Pharmacist contributions as members of the multidisciplinary ICU team

Chest

Volumn 144, Issue 5, 2013, Pages 1687-1695

  Preslaski, Candice R ^a   Lat, Ishaq ^d   MacLaren, Robert ^b   Poston, Jason ^c  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; HEPARIN; SEDATIVE AGENT; VANCOMYCIN;

ANALGESIA; ANTICOAGULANT THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; CLINICAL PHARMACY; CRITICALLY ILL PATIENT; DECISION MAKING; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EMERGENCY CARE; HEALTH CARE DELIVERY; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HEPARIN INDUCED THROMBOCYTOPENIA; HOLISTIC CARE; HUMAN; INFECTION CONTROL; INTENSIVE CARE; INTENSIVE CARE UNIT; LENGTH OF STAY; MEDICATION ERROR; MORBIDITY; MORTALITY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PATIENT CARE; PHARMACIST; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESUSCITATION; SALARY; SEDATION; SYSTEMATIC REVIEW;

EID: 84887494704     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1615     Document Type: Article

References (55)

1. Dasta JF. Critical care. Ann Pharmacother. 2006;40(4):736-737.
2. The definition of clinical pharmacy. American College of Clinical Pharmacy website. http://www.accp. com/docs/positions/commentaries/ Clinpharmdefnfinal.pdf. Accessed November 23, 2012.
3. Scope of contemporary pharmacy practice: roles, responsibilities, and functions of pharmacists and pharmacy technicians. Council on Credentialing in Pharmacy website. http://www.pharmacycredentialing.org/Contemporary-Pharmacy- Practice.pdf. Accessed November 23, 2012.
4. Rudis MI, Brandl KM; Society of Critical Care Medicine and American College of Clinical Pharmacy Task Force on Critical Care Pharmacy Services Position paper on critical care pharmacy services. Crit Care Med. 2000;28(11):3746-3750.
5. Haupt MT, Bekes CE, Brilli RJ, et al; Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Guidelines on critical care services and personnel: recommendations based on a system of categorization of three levels of care. Crit Care Med. 2003;31(11):2677-2683.
6. Brilli RJ, Spevetz A, Branson RD, et al; American College of Critical Care Medicine Task Force on Models of Critical Care Delivery; American College of Critical Care Medicine Guidelines for the Definition of an Intensivist and the Practice of Critical Care Medicine. Critical care delivery in the intensive care unit: defining clinical roles and the best practice model. Crit Care Med. 2001;29(10):2007-2019.
7. MacLaren R, Devlin JW, Martin SJ, Dasta JF, Rudis MI, Bond CA. Critical care pharmacy services in United States hospitals. Ann Pharmacother. 2006;40(4):612-618.
8. Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and hospital mortality rates. Pharmacotherapy. 2007;27(4):481-493.
9. MacLaren R, Brett McQueen R, Campbell J. Clinical and financial impact of pharmacy services in the intensive care unit: pharmacist and prescriber perceptions. Pharmacotherapy 2013;33(4):401-410.
10. Carver PL, Lin SW, De Pestel DD, Newton DW. Impact of mecA gene testing and intervention by infectious disease clinical pharmacists on time to optimal antimicrobial therapy for Staphylococcus aureus bacteremia at a University Hospital. J Clin Microbiol. 2008;46(7):2381-2383.
11. Kuper KM, Septimus EJ. Health-care-associated infections: the legislative perspective and the pharmacist's role. Am J Health Syst Pharm. 2009;66(5):488-494.
12. Dellit TH, Owens RC, McGowan JE Jr, et al; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159-177.
13. ASHP statement on the pharmacist's role in antimicrobial stewardship and infection prevention and control. Am J Health Syst Pharm. 2010;67(7):575-577.
14. Gentry CA, Greenfield RA, Slater LN, Wack M, Huycke MM. Outcomes of an antimicrobial control program in a teaching hospital. Am J Health Syst Pharm. 2000;57(3):268-274.
15. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist-managed antimicrobial prophylaxis in surgical patients. Am J Health Syst Pharm. 2007;64(18):1935-1942.
16. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy. Am J Health Syst Pharm. 2005;62(15):1596-1605.
17. Wade WE, McCall CY. Pharmacist-managed aminoglycoside therapy in combination with a beta-lactam agent in the treatment of nosocomial pneumonia in critically ill patients. Pharmacotherapy. 1995;15(2):216-219.
18. Streetman DS, Nafziger AN, Destache CJ, Bertino AS Jr. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy. 2001;21(4):443-451.
19. MacLaren R, Bond CA, Martin SJ, Fike D. Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections. Crit Care Med 2008;36(12):3184-3189.
20. National patient safety goals effective January 1, 2012. The Joint Commission website. http://www.jointcommission.org/assets/1/6/2013-CAH-NPSG- final-10-23.pdf. Accessed January 5, 2013.
21. Dobesh PP, Phillips KW, Haines ST. Improving the use of anticoagulant therapies in acutely ill medical patients. Am J Health Syst Pharm. 2008;65(15 suppl 7):S5-S12.
22. Petitta A. Assessingthevalueofpharmacists'health-systemwide services: clinical pathways and treatment guidelines. Pharmacotherapy. 2000;20(10 pt 2):327S-332S.
23. To L, Schillig JM, Desmet BD, Kuriakose P, Szandzik EG, Kalus JS. Impact of a pharmacist-directed anticoagulation service on the quality and safety of heparin-induced thrombocytopenia management. Ann Pharmacother. 2011;45:195-200.
24. MacLaren R, Bond CA. Effects of pharmacist participation in intensive care units on clinical and economic outcomes of critically ill patients with thromboembolic or infarctionrelated events. Pharmacotherapy. 2009;29(7):761-768.
25. Bond CA, Raehl CL. Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions. Pharmacotherapy. 2004;24(8):953-963.
26. Dager WE, Branch JM, King JH, et al. Optimization of inpatient warfarin therapy: impact of daily consultation by a pharmacist-managed anticoagulation service. Ann Pharmacother. 2000;34(5):567-572.
27. Jacobi J, Fraser GL, Coursin DB, et al; Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists (ASHP), American College of Chest Physicians. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30(1):119-141.
28. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000;342(20):1471-1477.
29. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet. 2008;371(9607):126-134.
30. MacLaren R, Plamondon J, Ramsay K, Rocker G, Patrick W, Hall R. A prospective evaluation of empiric versus protocolbased sedation and analgesia. Pharmacotherapy. 2000;20(6):662-672.
31. Marshall J, Finn CA, Theodore AC. Impact of a clinical pharmacist-enforced intensive care unit sedation protocol on duration of mechanical ventilation and hospital stay. Crit Care Med. 2008;36(2):427-433.
32. Devlin JW, Holbrook AM, Fuller HD. The effect of ICU seda tion guidelines and pharmacist interventions on clinical out comes and drug cost. Ann Pharmacother. 1997;31(6):689-695.
33. Devlin JW, Nasraway SA Jr. Reversing oversedation in the intensive care unit: the role of pharmacists in energizing guideline efforts and overcoming protocol fatigue. Crit Care Med. 2008;36(2):626-628.
34. Forni A, Skehan N, Hartman CA, et al. Evaluation of the impact of a tele-ICU pharmacist on the management of sedation in critically ill mechanically ventilated patients. Ann Pharmacother. 2010;44(3):432-438.
35. Draper HM, Eppert JA. Association of pharmacist presence on compliance with advanced cardiac life support guidelines during in-hospital cardiac arrest. Ann Pharmacother. 2008;42(4):469-474.
36. To err is human: building a safer health system. Institute of Medicine website. http://www.iom.edu/~/media/Files/Report%20Files/1999/To-Err-is-Human/ To%20Err%20is%20 Human%201999%20%20report%20briefpdf Accessed November 23, 2012.
37. Landrigan CP, Parry GJ, Bones CB, Hackbarth AD, Goldmann DA, Sharek PJ. Temporal trends in rates of patient harm resulting from medical care. N Engl J Med. 2010;363(22):2124-2134.
38. Bertsche T, Mayer Y, Stahl R, Hoppe-Tichy T, Encke J, Haefeli WE. Prevention of intravenous drug incompatibilities in an intensive care unit. Am J Health Syst Pharm. 2008;65(19):1834-1840.
39. Brown JN, Barnes CL, Beasley B, Cisneros R, Pound M, Herring C. Effect of pharmacists on medication errors in an emergency department. Am J Health Syst Pharm. 2008;65(4):330-333.
40. Calabrese AD, Erstad BL, Brandl K, Barletta JF, Kane SL, Sherman DS. Medication administration errors in adult patients in the ICU. Intensive Care Med. 2001;27(10):1592-1598.
41. Klopotowska JE, Kuiper R, van Kan HJ, et al. On-ward participation of a hospital pharmacist in a Dutch intensive care unit reduces prescribing errors and related patient harm: an intervention study. Crit Care. 2010;14(5):R174.
42. Kopp BJ, Mrsan M, Erstad BL, Duby JJ. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm. 2007;64(23):2483-2487.
43. Rivkin A, Yin H. Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients. J Crit Care. 2011;26(1):104.e1-104.e6.
44. Weant KA, Humphries RL, Hite K, Armitstead JA. Effect of emergency medicine pharmacists on medication-error reporting in an emergency department. Am J Health Syst Pharm 2010;67(21):1851-1855.
45. Valentin A, Capuzzo M, Guidet B, et al; Research Group on Quality Improvement of the European Society of Intensive Care Medicine (ESICM); Sentinel Events Evaluation (SEE) Study Investigators. Errors in administration of parenteral drugs in intensive care units: multinational prospective study. BMJ. 2009;338:b814.
46. Vasileff HM, Whitten LE, Pink JA, Goldsworthy SJ, Angley MT The effect on medication errors of pharmacists charting medication in an emergency department. Pharm World Sci 2009;31(3):373-379.
47. Viktil KK, Blix HS. The impact of clinical pharmacists on drug-related problems and clinical outcomes. Basic Clin Pharmacol Toxicol. 2008;102(3):275-280.
48. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy. 2002;22(2):134-147.
49. Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282(3):267-270.
50. Ng TM, Bell AM, Hong C, et al. Pharmacist monitoring of QTc interval-prolonging medications in critically ill medical patients: a pilot study. Ann Pharmacother. 2008;42(4):475-482.
51. Schumock GT, Meek PD, Ploetz PA, Vermeulen LC; The Publications Committee of the American College of Clinical Pharmacy. Economic evaluations of clinical pharmacy services-1988-1995. Pharmacotherapy. 1996;16(6):1188-1208.
52. Schumock GT, Butler MG, Meek PD, Vermeulen LC, Arondekar BV, Bauman JL; 2002 Task Force on Economic Evaluation of Clinical Pharmacy Services of the American College of Clinical Pharmacy. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003;23(1):113-132.
53. Emanuel E, Tanden N, Altman S, et al. A systemic approach to containing health care spending. N Engl J Med. 2012;367(10):949-954.
54. Rauh SS, Wadsworth EB, Weeks WB, Weinstein JN. The savings illusion-why clinical quality improvement fails to deliver bottom-line results. N Engl J Med. 2011;365(26):e48.
55. Dasta JF, Kane-Gill SL, Pencina M, et al. A cost-minimization analysis of dexmedetomidine compared with midazolam for long-term sedation in the intensive care unit. Crit Care Med 2010;38(2):497-503.